New minimed™ 780g system data demonstrates ability to address persistent blood sugar challenges for people with type 1 diabetes

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the minimed™ 780g system decreased rates of early morning hyperglycemia, known as dawn phenomenon, and improved overnight sleep dublin and orlando, fla. , june 21, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, is presenting a comprehensive body of new data at the american diabetes association's (ada) 84th scientific sessions that showcases the benefits of the minimed™ 780g system.
MDT Ratings Summary
MDT Quant Ranking